U.S. pauses distribution of Lilly’s COVID-19 antibody therapies

PUBLISHED: Fri, 25 Jun 2021 17:19:53 GMT
Share

June 25 (Reuters) – U.S. health officials on Friday paused the distribution of Eli Lilly’s COVID-19 antibody therapies – bamlanivimab and etesevimab together and etesevimab alone – as they fail to show effectiveness against the Brazil and South Africa variants of the coronavirus. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)

Sign Up for Our Newsletter Daily Update

Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.

(c) Copyright Thomson Reuters 2021. Click For Restrictions – https://agency.reuters.com/en/copyright.html